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Abstract: The elaboration of a pharmacophore model for thed opioid receptor selective ligand
JOM-13 (Tyr–c[D-Cys–Phe–D-Pen]OH) and the parallel, independent development of a structural
model of thed receptor are summarized. Although the backbone conformation of JOM-13’s
tripeptide cycle is well defined, considerable conformational lability is evident in the Tyr1 residue
and in the Phe3 side chain, key pharmacophore elements of the ligand. Replacement of these flexible
features of the ligand by more conformationally restricted analogues and subsequent correlation of
receptor binding and conformational properties allowed the number of possible binding conforma-
tions of JOM-13 to be reduced to two. Of these, one was chosen as more likely, based on its better
superposition with other conformationally constrainedd receptor ligands. Our model of thed opioid
receptor, constructed using a general approach that we have developed for all rhodopsin-like G
protein-coupled receptors, contains a large cavity within the transmembrane domain that displays
excellent complementarity in both shape and polarity to JOM-13 and otherd ligands. This binding
pocket, however,cannotaccommodate the conformer of JOM-13 preferred from analysis of ligands,
alone. Rather, only the “alternate” allowed conformer, identified from analysis of the ligands but
“disfavored” because it does not permit simultaneous superposition of all pharmacophore elements
of JOM-13 with otherd ligands, fits the binding site. These results argue against a simple view of
a single, common fit to a receptor binding site and suggest, instead, that at least some binding site
interactions of different ligands may differ.© 2000 John Wiley & Sons, Inc. Biopoly 51:
426–439, 1999
Keywords: bioactive conformation; conformationally restricted peptides; G protein coupled re-
ceptors; ligand–receptor interactions; molecular recognition; opioid peptides
INTRODUCTION
An understanding of the details of molecular recog-
nition between a ligand and its macromolecular target
is central to efforts at truly “rational” (structure-
based) drug design. For ligands whose targets are
water-soluble proteins, such an understanding can of-
ten be gained directly by x-ray structure determination
of the ligand–protein complex. This approach has
been especially valuable for probing the molecular
details of enzyme–substrate/inhibitor interactions and
has facilitated the development of effective inhibitors
of many enzymes with perhaps the most notable and
certainly the most thoroughly studied being HIV pro-
tease.1 The elucidation of ligand interactions with
membrane proteins, however, poses serious problems
that arise from the difficulty of high-resolution struc-
ture determination of these proteins due to limited
crystallization successes and difficulties in maintain-
ing native-like function when the protein is removed
from the membrane. Consequently, despite the fact
that; 30% of the proteins encoded in the genome are
predicted to have at least one transmembrane seg-
ment,2 membrane proteins constitute only; 0.2% of
all reported high-resolution experimental protein
structures. Given the considerable obstacles to struc-
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tural elucidation of membrane proteins, information
about ligand interactions with membrane-bound re-
ceptors has typically been limited to that which can be
inferred from ligand structure–activity information
and studies aimed at revealing the ligand’s binding
conformation. The inferred receptor binding site fea-
tures are necessarily quite crude and fall far short of
the level of detail needed for “rational” design.
Opioid ligand–receptor interactions provide a typ-
ical example of this scenario. Opioid receptors belong
to the rhodopsin-like G protein-coupled receptor
(GPCR) family, a large (. 1000 sequences) group of
structurally related transmembrane proteins that in-
cludes receptors for ligands of vastly varying size
(biogenic amine to glycoprotein).3 Despite many
years of study, no experimental, high-resolution struc-
ture has been determined for any GPCR. Conse-
quently, efforts to explain the molecular basis for
opioid ligand–receptor interaction have focused on
structural and conformational features of the ligand.
For flexible native ligands (such as the endogenous
opioid peptides), whose conformations are highly de-
pendent on their environment, conformationally con-
strained analogues must be employed if extrapolation
of the free ligand’s conformational features to that of
the bound ligand is to have any significance. In the
first part of this review, the development of ad opioid
ligand pharmacophore model, based upon a series of
such conformationally constrained ligands, will be
described.
Although no high-resolution experimental struc-
tures are available for any GPCR, a large number of
structural models have been proposed. The ap-
proaches used to generate these structures have en-
compassed many computational/modeling methods
and have typically started from low resolution elec-
tron microscopy (EM) data for rhodopsin.4–6 Often
the resulting models are rather crude but are nonethe-
less useful for the design of receptor mutagenesis
studies aimed, for example, at delineating residues
participating in ligand binding. Several years ago we
began the development of a new approach for con-
structing more accurate models of GPCRs.7 This ap-
proach is based upon the analysis of a large number of
GPCR sequences to identify proximal pairs of hydro-
gen-bonded residues and the use of the resulting dis-
tance constraints for distance geometry refinement of
an initial, crude model based upon the low-resolution
rhodopsin EM data. As discussed below, the resulting
; 30 models, which include rhodopsin7 and thed, m,
and k opioid receptors,8 are consistent with a vast
collection of experimental data and are supported by
structural and energetic considerations.
The existence of a reliabled opioid ligand phar-
macophore model and the wealth of structure activity
data available ford ligands provide the opportunity
FIGURE 1 Peptide ligands for thed opioid receptor.
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for verification of ourd opioid receptor model through
ligand docking. In this report we review the develop-
ment of both ad ligand pharmacophore model and a
high-resolution model of thed receptor, and demon-
strate that docking of these two independently derived
structures is consistent withd ligand structure–activ-
ity information.
THE DEVELOPMENT OF A d OPIOID
LIGAND PHARMACOPHORE MODEL
Since direct structural analysis of a ligand–receptor
complex usually presents severe experimental diffi-
culties, the development of a model for ligand–recep-
tor binding typically relies on evaluation of the li-
gand’s bioactive conformation, determined in the ab-
sence of receptor. For the necessary extrapolation of
the “receptor-free” solution or solid state ligand con-
formation to that of the ligand bound to the receptor to
be valid, the ligand must have limited conformational
lability to assure that its conformation is environment
independent. The native opioid pentapeptides,
leucine- and methionine-enkephalin (Figure 1), how-
ever, are quite flexible, and hence are unsuited for
such study. The incorporation of side-chain to side-
chain disulfide cyclization in thed receptor selective
analogue [D-Pen2, D-Pen5]enkephalin (Tyr–c[D-Pen–
Gly–Phe–D-Pen]OH, DPDPE, Figure 1)9 significantly
reduces conformational freedom, and consequently,
DPDPE has been a frequent target for conformational
analysis.10–14 Many of these conformational studies
have resulted, however, in discrepant conclusions, the
likely result of residual conformational freedom in
DPDPE. The most likely source of this flexibility in
the DPDPE backbone is the Gly residue. While pur-
suing several approaches to reduce the backbone flex-
ibility of DPDPE, we examined the effect of simply
eliminating this Gly residue. This led, in a straight-
forward way, to the tetrapeptide Tyr–c[D-Cys–Phe–
D-Pen]OH (JOM-13, Figure 1),15 which displays high
d receptor affinity, while retaining substantiald selec-
tivity.
A conformational search/molecular mechanics
study of JOM-13 revealed the existence of two major
conformational families of the cyclic tripeptide frag-
ment.16 Both conformational families exhibited simi-
lar conformations within the backbone of this tripep-
tide segment, but differed in the conformational fea-
tures of the disulfide. These results were supported by
nmr data16 that clearly identified two sets of reso-
nances whose differences were most pronounced for
the D-Cys2 and D-Pen4 residues, consistent with the
presence of two distinct disulfide conformers. x-Ray
crystallography of JOM-1316 confirmed the existence
of two conformers of the tripeptide cycle in the unit
cell, one conformer falling within each of the two
major conformational families found in the computa-
tional study.
The excellent agreement among the different con-
formational studies provided convincing evidence that
the backbone conformation of the tripeptide cycle of
JOM-13 is well defined and environment indepen-
dent. However, it was clear from the conformational
search/molecular mechanics study that the backbone
conformation of the exocyclic Tyr1 residue and the
FIGURE 2 Superposition (stereoview) of 20 lowest energy conformers (DG , 3 kcal/mol) of
JOM-13. Dashed and solid lines denote two families differing in disulfide geometry. Reprinted with
permission fromJournal of the American Chemical Society,1994, vol. 116, p. 430.
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side-chain conformations for Tyr1 and Phe3 are quite
variable. This can be seen in Figure 2, which depicts
the superposition of the 20 lowest energy conformers
found for JOM-13. In Figure 2 both the well-defined
conformational features of the cyclic tripeptide back-
bone and the conformational lability of Tyr and of the
Phe side chain are apparent. Unfortunately, these flex-
ible residues contain the key structural features for
opioid activity (“tyramine” amino and phenolic
groups and a second aromatic moiety)—hence the
constraints contained within JOM-13 are insufficient
for elucidating the key features of the bioactive con-
formation.
The conformational lability of JOM-13 leaves sev-
eral features of the bioactive conformation unre-
solved:c1 (the angle about the Tyr1 CaOCO bond);
w2 (the angle about the Cys2 NaOCa bond); andx11
andx13 (the angles about the CaOCb bonds of Tyr1
and Phe3, respectively). In order to remove this con-
formational uncertainty, we designed sets of ana-
logues in which conformationally labile components
of JOM-13 were replaced by more conformationally
well-defined elements.
Conformational Requirements of Tyr1
In the first set of analogues,17 the Tyr1 residue of
JOM-13 was replaced by several conformationally
constrained analogues of Tyr (Figure 3). Each of these
Tyr replacements has reduced flexibility compared to
Tyr, and importantly, each can sample a different
subset of the conformational space available to Tyr.
Consequently, if two or more of the analogues exam-
ined display similar binding affinity as JOM-13, then
the search for the bioactive conformational features of
Tyr1 in JOM-13 is simplified to a search within the
intersection of conformational space available to the
Tyr1 replacements in these active analogues. If, on the
other hand, only one of the Tyr-replacement ana-
logues displays “native-like” binding affinity, then the
bioactive conformation can be sought within the con-
formational space available only to that Tyr1 analogue
and Tyr itself. Of course, if none of the constrained
Tyr1 analogues of JOM-13 retains good binding af-
finity, the features of the bioactive conformation re-
main obscure. Fortunately, as shown in Table I, the
t-Hpp1 and c-Hpp1 [trans- and cis-3-(49-hydroxy)-
phenylproline, respectively] analogues of JOM-13
displayedd binding affinities comparable to that of
JOM-13, itself.17 Comparison of the conformational
tendencies of these two diastereomeric residues re-
duced the conformational possibilities for the Tyr
residue of JOM-13 to two, differing only in the pos-
sible choices ofw2 (the angle about the NaOCa bond
of D-Cys2), which could be either; 160° or; 70°. In
both conformersx1 for the Tyr side chain is; 180°
and c1 (the angle about the Tyr CaOCO bond) is
; 160°. Although both candidate bioactive conform-
ers are energetically similar, the conformation withw2
; 160° allowed better superposition of the high af-
finity c-Hpp1, t-Hpp1, and Tyr1 analogues with the
moderate affinity Hat1 (6-hydroxy-2-aminotetralin-2-
carboxylic acid) and Hai1 (6-hydroxy-2-aminoindan-
2-carboxylic acid) analogues. Consequently, we pro-
posed17 that this “preferred” conformer is more likely
to be the binding conformation than is the “alternate”
conformer (withw2 ; 70°). This proposal was based
on the seemingly reasonable assumption that the bind-
ing conformations of structurally similar ligands
should be similar and that these similar ligands should
interact in the same manner with the receptor. This
assumption is reconsidered below. To summarize,
then, the synthesis, pharmacological testing, and con-
formational analysis of JOM-13 analogues with con-









JOM-13 51.5 0.744 69.2
[t-Hpp1]JOM-13 105 0.66 159
[c-Hpp1]JOM-13 722 2.39 302
[Hai1]JOM-13 838 12.5 67.0
[Hat1]JOM-13 231 19.9 11.6
[D-Hat1]JOM-13 310 23.7 13.8
a Binding affinities atm and d receptors were determined by
displacement of [3H]DAMGO ([D-Ala2, NMePhe4, Gly5-ol]en-
kephalin) and [3H]DPDPE, respectively.17
FIGURE 3 Conformationally constrained Tyr1 replace-
ments.
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formationally constrained Tyr1 replacements allowed
key elements of the JOM-13 pharmacophore to be
determined (x11 ; 180°, c1 ; 160°) or limited (w2
; 160° or 70°). All that remained, then, was to
deduce the binding conformation of the Phe3 side
chain.
Conformational Requirements of Phe3
Figure 2 demonstrates that, in low energy conformers
of JOM-13, the Phe side chain can assume any of the
staggeredx1 conformers (x1 5 260°,160°, or 180°).
Substitution of Phe3 in JOM-13 by the des-hydroxy
counterparts (and hence Phe analogues) of the Tyr
replacements shown in Figure 3 and subsequent cor-
relation of binding affinity and conformational ten-
dencies is a logical approach for identifyingx1 of Phe
in the JOM-13 bioactive conformation. Unfortunately,
we observed that all these replacements resulted in
rather large (. 50-fold) reductions in binding affinity,
which is probably attributable to distortion of the
backbone conformation of the cyclic tripeptide caused
by cyclization of the Phe side chain to the backbone
Na or Ca. As an alternate approach, we prepared the
4 stereoisomers ofb-methyl Phe and incorporated
each of these as Phe3 replacements in JOM-13.18 The
rationale behind this well-studied approach is to ex-
ploit the steric property of theb-methyl to favor one
conformation ofx (Figure 4). Table II summarizes the
m andd binding affinities of the fourbMePhe3 ana-
logues of JOM-13 and additionally provides the rel-
ative energies of the residue 3 rotamers calculated for
each analogue.18 As can be seen from this table, in
[(2S, 3S)-MePhe3]JOM-13 and [(2R, 3R)-MePhe3]-
JOM-13, the analogues displaying the highestd affin-
ity, the same spatial orientation of the phenyl side
chain is strongly favored: thex1 5 260° rotamer of
the former is favored by 1.5–2.2 kcal/mole, while the
spatially equivalent (since thea stereochemistry is
inverted)x1 5 60° rotamer of the latter is favored by
more than 6 kcal/mole! These results strongly impli-
cate the presence of thex1 5 260° rotamer of Phe3 in
the binding conformer of JOM-13.
As a further test of this conclusion, we prepared
JOM-13 analogues in which Phe3 was replaced by
either dehydro-Z-phenylalanine (DZ-Phe) or dehydro-
E-phenylalanine (DE-Phe).19 Conformational analysis
had revealed that the former of these analogues could
be superimposed with JOM-13 in which the Phex1
5 260°, while the latter analogue superimposes with
JOM-13 conformers with the Phex1 5 180°. The
observation that [DZ-Phe3]JOM-13 displaysd recep-
tor binding affinity comparable to that of JOM-13,
itself (Ki 5 2.3 vs 0.74 nM), while [D
E-Phe3]JOM-
13 binds significantly more poorly (Ki 5 45 nM)
19
provides strong support for the proposed bioactive
conformation of the Phe side chain. Combined with
the conformational analysis of the JOM-13 tripeptide
cycle and the elucidation of the Tyr1 binding confor-
mation, the determination of the Phe binding rotamer
as5 260° allowed a complete binding conformation
FIGURE 4 Sterically preferred side-chain conformers of
bMePhe.
Table II Binding Affinities and Energy Differences of X3 Side-Chain Rotamers of JOM-13 andbMePhe3
Containing Analoguesa




JOM-13 51.5 0.744 0.1 0.0 0.9
[(2S, 3R)MePhe3]JOM-13 1000 12.3 0.2 0.0 2.0
[(2S, 3S)MePhe3]JOM-13 259 1.52 0.0 2.2 1.5
[(2R, 3S)MePhe3]JOM-13 .10,000 237 4.7 0.0 1.2
[(2R, 3R)MePhe3]JOM-13 .10,000 4.80 6.3 6.1 0.0
a Binding affinities atm andd receptors were determined by displacement of [3H]DAMGO ([D-Ala2, NMePhe4, Gly5-ol]enkephalin) and
[3H]DPDPE, respectively.18
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for JOM-13 and related analogues to be proposed.
This “proposed” conformation, withw2 ; 160°, and
the alternate conformer withw2 ; 70° (see discussion
above) are shown in Figure 5.
Although we had at this time proposed a bioac-
tive conformation of JOM-13, the choice of thew2
; 160° conformer rather than thew2 ; 70° con-
former was based solely on the better superposition
of high affinity and moderate affinity JOM-13 an-
alogues in the former case. Consequently, we were
interested in comparing both conformations with
those of other conformationally constrainedd li-
gands. Among the ligands chosen for comparison
were the relatively rigid alkaloids 7-spiroindany-
loxymorphone (SIOM), ad selective agonist,20 and
oxymorphindole (OMI), ad selective antagonist.21
As shown in Figure 6, the proposed (“preferred”)
JOM-13 binding conformer superimposes well with
both alkaloid ligands.22 In all cases the tyramine
regions of the ligands are similarly arranged, while
the second aromatic rings (the Phe side chain of
JOM-13 and the indanyl and indole moieties of
SIOM and OMI, respectively) occupy similar spa-
tial positions. It was further observed that these
second aromatic rings were coplanar in the agonists
JOM-13 and SIOM, but tilted in OMI, leading to
the suggestion that orientation of this aromatic ring
distinguishes agonist from antagonist binding.22 In
Figure 7, superposition of SIOM and OMI with
JOM-13 in its alternate conformer (from Figure 5)
is shown. This superposition clearly does not allow
simultaneous correspondence of the tyramine and
second aromatic regions. Therefore, we concluded
that the preferred JOM-13 binding conformer was
indeed correct and that even structurally diversed
ligands (and indeed, even agonists and antagonists)
bind very similarly. Of course, this supposition that
different ligands bind in a similar manner, while
comforting to those trying to interpret structure–
activity data in the absence of receptor structural
information, is not necessarily correct. Indeed, it
has been demonstrated that even structurally quite
similar ligands may bind to their common macro-
molecular target in quite different ways.23 Thus,
although structure–activity and conformation–ac-
tivity studies of ligands are very informative, they
are insufficient, by themselves, for confident deduc-
tions of how these ligands interact with their recep-
tors. Of course, an experimental structure for the
ligand–receptor complex would be the ideal, but
lacking this, an approach that allows the construc-
tion of reliable high resolution structural models of
the receptor can fill this gap.
FIGURE 5 Proposed (solid line) and “alternate” (dashed line) bioactive conformations of JOM-13.
FIGURE 6 Superposition of JOM-13 (proposed bioactive conformer, solid line), SIOM (dashed
line), and OMI (dotted line).
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DEVELOPMENT OF A NEW
APPROACH FOR MODELING G
PROTEIN-COUPLED RECEPTORS
As depicted in Figure 8 for thed opioid receptor,
GPCRs contain 7 transmembrane helices (TMH) con-
nected by three intracellular (IL) and three extracel-
lular (EL) loops. An additional intracellular loop,
IL-4, connects the C-terminal end of TMH VII to a
highly conserved palmitoylated cysteine in GPCRs.
The intra- and extracellular GPCR domains are criti-
cal to receptor function. The extracellular loops of
many GPCRs, including opioid receptors, are in-
volved in ligand binding (see, for example, Ref. 24),
while the intracellular loops and C-terminal region
interact with G-proteins, protein kinases, arrestins,
and other molecules involved in downstream events
of the transduction pathway.25–27
EM studies of several rhodopsins4–6have provided
low resolution (; 5–7 Å in the plane of the mem-
brane, much lower resolution perpendicular to the
membrane plane) structural data that clearly show
these receptors to contain the seven transmembrane
a-helices depicted in Figure 8. Furthermore, the pres-
ence, in each transmembrane helix, of several char-
acteristic residues conserved throughout the rhodop-
sin-like GPCRs indicates that all proteins in the
family share a common three-dimensional (3D) struc-
ture.28 The existence of a minimum sequence homol-
ogy of ; 20% between remotely related GPCRs sug-
gests a; 1.6–2.3 Å rms deviation (RMSD) of main-
chain atoms within thea-helical core, using a
FIGURE 7 Superposition of JOM-13 (alternate bioactive conformer, solid line), SIOM (dashed
line), and OMI (dotted line).
FIGURE 8 Serpentine model of thed opioid receptor. Shaded residues are those highly con-
served within the rhodopsin-like family of GPCRs.
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calibration curve relating the coordinate RMSD and
sequence identity for proteins with known 3D struc-
tures.29
GPCRs, especially rhodopsin itself, have been ex-
tensively studied by site-directed mutagenesis and by
a variety of physicochemical methods. These experi-
mental data and the analysis of variability and hydro-
phobicity patterns in amino acid sequences of GPCRs
allow the identification within the GPCR primary
sequence of the transmembrane helices and their un-
equivocal assignment to the peaks in the EM maps,28
and from this assignment, the construction of various
approximate GPCR models. Modeling of the trans-
membrane domain is simplified by the identification
of residues that are evolutionarily conserved or hy-
drophilic, or that are important for folding or ligand
binding. These residues form the protein interior, thus
defining a lipid-inaccessible surface of each trans-
membrane helix and placing a restriction on rotational
orientation of the helix and the depth of its immersion
into thea-bundle.28,30,31GPCR models typically have
been built from seven “ideal” helices with arbitrarily
chosen side-chain conformers (or without side chains
at all) to satisfy the EM maps, the restrictions on
rotational orientations of the helices, and constraints
derived from mutagenesis and cross-linking data.32–37
Such models are helpful for suggesting mutagenesis
studies, but are insufficiently precise to provide accu-
rate details of ligand–receptor recognition. During the
past few years we have developed a more precise
structure of the transmembranea-bundle based upon
the observation that numerous polar residues are
present within the transmembrane, hydrophobica-he-
lices of GPCRs. It is known that water-inaccessible,
polar side chains of proteins have a strong tendency to
form H bonds.38 In transmembranea-helices, back-
bone peptide groups are already paired (except for the
carbonyl “partners” of proline residues); hence, the
polar side chains must interact with each other to form
intra- or interhelical H bonds. If these H bonds can be
identified, then they can be used for refinement of a
crudea-bundle model (based upon the EM maps, as
described above) by distance geometry calculations,
much like nmr-derived experimental protein struc-
tures. The candidate H bonds indeed can be identified
from the analysis of sequence alignments as polar
residues, in intramembrane segments, which appear
and disappear simultaneously in various GPCRs, i.e.,
residues whose presence throughout the many GPCR
sequences is highly pairwise correlated. Such pair-
wise correlation suggests spatial proximity, which for
polar residues in a nonpolar environment connotes an
H-bond interaction. We had originally envisioned ap-
plying this procedure to an individual receptor se-
quence; however, it soon became clear that any single
GPCR has too few H-bonding constraints to lead to a
convergent structure. This obstacle was surmounted
by reasoning that, since the structure of thea-bundle
for all GPCRs must be very similar, the side-chain
H-bonds from many different GPCRs can be com-
bined to increase the number of constraints. Accord-
ingly, our initial receptor sequence (bovine rhodop-
sin) was “virtually mutated” to incorporate pairwise
correlated polar residues present in other GPCRs.
This “composite” receptor was then used to calculate,
via the distance geometry algorithm, an “average”
7-a-bundle structure. The computational procedure
employed, which we have described in detail else-
where,7 was organized as an iterative refinement with
evolving constraints. Examination of structures dur-
ing the iterative procedure led to the identification of
additional H-bond constraints (and to the identifica-
tion and elimination of “false positives”), which were
then included in subsequent iterations. The iterative
procedure began with the initial “crude” model of the
a-bundle and continued until every buried polar side
chain from eachof the 410 GPCRs considered (col-
lectively,.20,000 side chains) was able to participate
in at least one hydrogen bond in the final structure.
This “saturation of H-bonding potential” criterion was
very sensitive to errors during the refinement. Al-
though the transmembrane segments of individual
GPCRs are hydrophobic and contain less than 30%
polar residues, when 410 different amino acid se-
quences are simultaneously considered,all interheli-
cal contacts within thea-bundle are “labeled” by
polar side chains forming intramolecular H bonds,
usually in a group of related receptors. Displacement
of a-helices from their correct positions breaks some
H bonds, producing unpaired polar side chains within
the lipid bilayer in tens or hundreds of GPCRs.
Although the 7-a bundles of all rhodopsin-family
GPCRs can be expected to be structurally similar,
they are unlikely to be identical. Further, due to the
incorporation of constraints from many GPCRs in the
calculation of the “average” model, it is likely that
this model is overconstrained. Hence, the calculation
of a specific receptor model, using the same iterative
distance geometry approach, utilizes only those hy-
drogen-bonding constraints applicable to that recep-
tor, while using the average model to constrain the
positions of the helices, but allowing; 1.0 Å devia-
tions from the imposed interhelical constraints to al-
low the a bundle to “relax.” The resulting specific
receptor models demonstrate excellent packing and
polarity matching, have all side chains in Ramachan-
dran-allowed conformations, and are in excellent
agreement with available experimental data.7,8,39
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A number of additional observations further sup-
port the validity of our calculated 7-a bundle struc-
tures:
1. Close packing of nonpolar side chains and cor-
related replacements.In comparisons of dis-
tinctly different GPCRs (sequence identity 20–
25%), many examples of correlated replace-
ments throughout the transmembrane domain
are observed. The appearance of a bulky (espe-
cially aromatic) side chain in one receptor (in
place of a smaller side chain in another recep-
tor) is usually accompanied by a concomitant
decrease of volume in several surrounding side
chains to maintain good packing of the struc-
ture.7
2. Clustering of conserved residues.Forty evolu-
tionarily conserved GPCR residues form a sin-
gle continuous domain in the intracellular re-
gion of the 7-a bundle. This domain is com-
posed of a large aliphatic cluster and six smaller
clusters of polar and aromatic side chains, sim-
ilar to the clustering of conserved residues ob-
served in proteins with known 3D structures.40
3. Clustering of residues with similar polarities.In
the calculated GPCR models, all polar and non-
polar residues are segregated into clusters of
similar polarity. Moreover, the side chains of
different polarity tend to be organized as in a
“polarity gradient” with the most polar groups
(from Asp, Asn, Glu, Gln, Lys, etc., residues)
separated from the least polar aliphatic groups
by aromatic and sulfur-containing groups of
intermediate polarity.7 Such an arrangement
can be expected to be energetically favorable.
Opioid Receptor Models
Models for the 7-a bundles of thed, m, andk opioid
receptors were constructed using the approach de-
scribed above. However, although the ligand binding
pocket consists mainly of residues from the trans-
membranea-bundle, the extracellular loops of opioid
receptors have also been shown to be important for
interactions with many ligands.41–45 Hence, loop
modeling, using a modified version of the distance
geometry refinement used for calculation of the trans-
membranea-bundle, was also initiated.8 The short
(5–7 residues, Figure 8) EL-1 and EL-3 segments can
be viewed as merely linking TMHs; however the
longer EL-2 (20 residues in thed receptor) partially
covers the binding cavity between helices III–VII in
the transmembranea-bundle model and can interact
directly with opioid ligands.
Modeling of EL-2 presents additional difficulties
compared with the transmembrane domains, since
specific secondary structure cannot be assumed. How-
ever, this loop is constrained by the attachment of its
ends to the tops of TMH IV and V and its additional
covalent attachment, via a disulfide, to the end of
TMH III (Figure 8), giving this loop a U-like shape.
Both branches of this “U” are too short to form any
additionala-helices in the calculated models of the
transmembrane domain, and the geometrical con-
straints imposed by their attachment to TMH III, IV,
and V forces them to adopt extended structures. Ex-
amination of the sequence patterns in this loop for all
three opioid receptors suggests that the two extended
antiparallel stretches of EL-2 near the conserved di-
sulfide bond are paired in ab-hairpin, while the
remainder of EL-2, connecting theb-hairpin to heli-
ces IV and V, adopts nonregular structure. Further
details of the proposed conformation of EL-2 are
presented elsewhere.8
Our d (andm andk) opioid receptor model has a
large cavity in the extracellular side of the transmem-
brane bundle between helices III–VII that is partially
covered by theb-hairpin formed by EL-2. This cavity,
which defines the binding pocket, is formed mainly by
nonpolar residues but contains several polar residues
as well (Asp128, Tyr129, Asp210, Lys214, His278). Some
side chains oriented toward the cavity appear to be
flexible. Side-chain reorientation of Leu125 (x1
5 260°,x2 5 180°; orx1 5 180°,x2 5 60°), Asp128
(x1 5 260° or 180°), Tyr129 (x1 5 260° or 180°),
Asp210 (x1 5 180° or 660°), Lys214 (x1 5 180° or
260°, x2–x4 5 180° or660°), Leu300 (x1 5 260°,
x2 5 180°; or x1 5 180°, x2 5 60°), or Trp284 (x2
5 690°) during distance geometry calculations does
not affect the scoring functions or the overall calcu-
lated structures (RMSD) for all Ca atoms, 0.5 Å)
but does change the shape of the binding pocket. The
flexibility of these residues allows their adjustment
during ligand fitting. Indeed, the docking of different
ligands requires the rotation of some of these residues
to avoid steric hindrances.8
The 36 residues of thed receptor in the vicinity of
JOM-13 (proximity of 6 Å) are shown in Figure 9.
Many of these residues are conserved ind, m, andk
opioid receptors and interact with the common tyra-
mine feature of opioid ligands, while other residues
are variable and may account for selective receptor–
ligand interactions. The “variable region” consists
mostly of residues from the ends of the transmem-
brane helices and from the extracellular loops. Dock-
ing of opioid ligands was directed by positioning their
common tyramine moiety on the bottom of cavity
with the protonated amine oriented toward Asp128
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(TMH III) and the hydroxyl group oriented toward
His278 (TMH VI). The importance of these ligand
functional groups and the corresponding receptor res-
idues has been convincingly implicated by mutagen-
esis and ligand structure–activity studies. The rest of
the tyramine moiety was positioned in the cavity to fill
the empty space and to avoid steric hindrances.
JOM-13 was positioned in thed receptor binding
pocket using the experimental crystal structure of this
peptide’s 11-membered cycle, but with adjusted tor-
sion angles for the exocyclic Tyr1 residue andx1
angle of Phe3. This positioning can only be done in
the trans (x1 ; 180°) orientation of the Tyr1 side
chain, in agreement with our structure–activity results
for X1-JOM-13 analogues, described above. Next, the
gauche1 (x1 5 260°) orientation of Phe3 was chosen
based on the residue 3 structure–activity results for
JOM-13 analogues.18,19 Then, the spatial position of
the disulfide-bridged, 11-membered ring relative to
the fixed Tyr1 was adjusted by rotating torsion angles
c1 (of Tyr1) andw2 (of D-Cys2). As described above,
two alternative conformers of JOM-13, withw angle
of D-Cys2 ; 160° or ; 70° were found to be ener-
getically plausible and consistent with structure–ac-
tivity data. Of these, thew2 ; 160° conformer was
proposed to be the binding conformation since it
provided a better superposition of all pharmacophoric
elements (Tyr1 residue and Phe3 side chain) in differ-
ent analogues of JOM-13.17,18 However, ligand–re-
ceptor docking of JOM-13 clearly shows thatonly the
alternate, w2 ; 70°, conformer can fit the binding
pocket. Indeed, the receptor models show that a pre-
cise superposition of all pharmacophoric elements in
different ligands is not required and that, even in
similar cyclic peptides, the functionally important
phenylalanine aromatic ring may slightly change ori-
entation and location. This is discussed in further
detail elsewhere.8
The bound conformation of JOM-13 geometrically
fits the binding pocket of thed-receptor and forms a
number of complex-stabilizing H-bonds and hydro-
phobic contacts with surrounding receptor residues
(Figure 9). The binding pocket can be considered to
be composed of subsites that are complementary to
individual structural elements of JOM-13, i.e., its Tyr1
residue, Phe3 side chain, and C-terminal COO2
group.
Tyr1 Subsite
The positively charged nitrogen of Tyr1 of JOM-13
participates in an ionic interaction with the side chain
carboxyl of Asp128 (TMH III) and is surrounded by
polar residues from TMH I (Tyr56), TMH II (Gln105),
and TMH VII (His301and Tyr308) (Figure 10). The Oh
group of Tyr1 forms an H bond with Nd of His278
(TMH VI). The aromatic ring of Tyr1 occupies the
bottom of the cavity between TMH III, TMH V, and
TMH VI and interacts with sulfur-containing (Met132,
Cys303), aromatic (Tyr129, Phe218, Trp274), and ali-
phatic (Leu125, Ile277, Val281, Ile304) residues. There
are a few empty regions around Tyr1 in the cavity,
suggesting that Tyr1 of JOM-13 may have residual
flexibility inside the pocket, with the aromatic ring
occupying essentially the same spatial position for
different combination ofc1 and w2 angles. The side
chain of Tyr129 (TMH III) also retains flexibility and
can assumetrans(x1 5 180°) orgauche(x1 5 260°)
rotamers without substantial steric hindrance with the
ligand. In the latter case, Tyr129 can form an H-bond
with the backbone carbonyl of the Tyr residue of
JOM-13 (not shown). The unoccupied space around
Tyr1 allows the binding site to accommodate methyl
groups in the 29 and 69 position of Tyr1 or the extra
ring of Hpp1, consistent with the high affinity ob-
served for the corresponding JOM-13 analogues.17 On
the other hand, the CaH atom of Tyr1 is in close
contact with Leu125 or Tyr129 (for x1 5 260°) and an
additional Ca-methyl group incorporated here would
FIGURE 9 JOM-13 (blue) in thed opioid receptor binding pocket (stereoview). Conserved and
variable (inm, d, andk receptors) receptor residues are denoted by red and green, respectively.
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experience steric hindrance with the side chain of
Leu125 or the aromatic ring of Tyr129, consistent with
the decreased affinities of CaMeTyr1, Hai1, and Hat1
analogues of JOM-13.17 The proximity between the
first peptide group of the ligand and the Leu125 side
chain precludes the accommodation of Na substitu-
tions in residue 2 of the ligand. This is consistent with
the low affinity of [NMe-D-Cys2]JOM-13.46 Replace-
ments of Tyr1 by D-Tyr1 and HO-Tic1 (1,2,3,4,-tetra-
hydro-7-hydroxyisoquinoline-3-carboxylic acid) resi-
dues, which have entirely different orientations of the
tyrosine ring within the pocket, produce numerous
overlaps with surrounding receptor atoms, consistent
with the observed low binding affinities ofD-Tyr1 and
HO-Tic1 analogues of JOM-13 (Ref. 17, and unpub-
lished observations).
Phe3 Subsite
The Phe3 side chain of JOM-13 (x1 5 260°) is
positioned on the side of the cavity between helices II,
III, and VII. The aromatic ring of Phe3 is located
below the conserved Cys121OCys198 disulfide bond
and also interacts with residues from TMH II (Gln105,
Tyr109), TMH III (Val 124, Leu125), and TMH VII
(Val297, Leu300, His301, and Ile304) (see Figure 11).
The presence of significant empty space in this region
of the binding cavity could allow a reorientation of the
Phe3 side chain fromx1 5 260° tox1 5 180°. In this
case, the aromatic ring of Phe3 would occupy an
alternate position, above the disulfide bond, and
would interact primarily with residues from EL-2
(Leu200, Cys198), EL-3 (Leu295) and the extracellular
terminus of TMH III (Cys121, Lys122). However, in
our model, this would create steric hindrance between
Phe3 of the peptide and surrounding residues of the
receptor. Therefore, the preferred orientation of Phe3
in the d receptor model isgauche(x1 5 260°), in
agreement with the high affinities of [DzPhe3] and
[(2S, 3S)MePhe3] analogues of JOM-13,18,19in which
thex1 angles of residue 3 are fixed in this orientation.
The reduced d binding affinity observed for
[DEPhe3]JOM-13, wherex1 of Phe3 is fixed at 180°,19
is also consistent with the model. The size of the
cavity in the Phe3 subsite is large enough to accom-
modate even bulkier side chains, such as those of Nal3
FIGURE 10 JOM-13 (blue) in thed opioid receptor binding pocket. The ligand’s Tyr residue and
the corresponding receptor subsite residues are should in the “licorice” representation.
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(naphthylalanine) or Trp3 in the samex1 5 260°
orientation, consistent with the high affinity of the
corresponding analogues of JOM-13.47
COO2 Subsite
The C-terminal COO2 group of JOM-13 forms an
ionic interaction with the« amine of Lys214 (x1
5 260°, x2–x4 5 180°) buried inside thea-bundle
(Figure 12). This ionic interaction between these op-
positely charged groups is lacking for carboxamide
terminal peptide ligands, such as the carboxamide
analogue of JOM-13, which displays a 10-fold reduc-
tion in d binding affinity.15 A terminal carboxamide
does, however, improve binding tom receptors, con-
sistent with the well established observation that neg-
atively charged groups in this region of the ligand
(either C-terminal in tetrapeptide and pentapeptide
opioids or residue 4 side chains in deltorphins) ham-
per binding to this receptor. Interestingly, Lys214 of
the d receptor is conserved inm (and k) receptors,
however Asp210 is replaced by Glu in them receptor.
Further, our models suggest that peptide ligands are
slightly shifted in them binding site relative to thed
binding site. Together these factors result in an ad-
verse electrostatic interaction between the negative
charges of the ligand and this Glu side chain, consis-
tent with the observed poorm receptor binding affinity
of such ligands.
In summary, we have demonstrated that our ligand
pharmacophore model of JOM-13, developed from
conformation–activity analysis of this ligand and a
series of further conformationally constrained ana-
logues, provides an excellent fit to the binding pocket
of our d opioid receptor model, constructed without
any ligand structure bias. The observation that, of the
two possible ligand bioactive conformations proposed
from study of the ligand alone, only the “alternate”
conformer, which provides much less satisfactory
overlap with other conformationally restrictedd li-
gands, can be accommodated, reflects the fact that
some subsites of the binding pocket have sufficient
space and conformational variability to adjust to dif-
ferent orientations of pharmacophore elements com-
mon among different ligands. Thus, the requisite tyra-
mine moiety of opioid ligands interacts similarly at
FIGURE 11 JOM-13 (blue) in thed opioid receptor binding pocket. The ligand’s Phe residue and
the corresponding receptor subsite residues are should in the licorice representation.
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thed receptor, while the binding subsite of the second
aromatic ring arising from the Phe3 or Phe4 residue of
opioid peptides or the indole and indanyl moieties of
OMI and SIOM, respectively, allows more variability
in the ligand. The fact that an incorrect choice of the
bioactive conformation of JOM-13 would be made
based only on the ligand studies underscores, of
course, the value of complementary receptor model-
ing.
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